Rivaroxaban is a new oral anticoagulant, direct factor Xa inhibitor, developed by Bayer HealthCare and sold under the trade name Xarelto®. It is approved in three indications in Europe: prevention of stroke and systemic embolism...
Read more
For every Heparin Induced Thrombocytopenia (HIT) suspicion. A rapid and specific exclusion of Heparin Induced Thrombocytopenia in 10 minutes. Diagnosing and treating Heparin Induced Thrombocytopenia (HIT) represent a challenge...
Read more
The only available automated test to determine the procoagulant activity of phospholipids.
Read more
This innovating test is an indirect marker of Tissue Factor exposure In Vivo.
Read more
12